← Back to patent-cliff list
Triptorelin Pamoate
Tier C — Watch / tradeTriptorelin Pamoate
Actavis A/S
Originator
2000
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：GnRHR
Brand：Trelstar (pamoate salt), Moapar (pamoate salt), Salvacyl, Trelstar LA, Trelstar Depot (pamoate salt), Trellasar (pamoate salt), Decapeptyl SR (pamoate salt), Pamorelin LA (pamoate salt)
Indications (approved)：性早熟, Prostate cancer
Regional status
US
Approved
2000-06-15
EU
Discontinued
2007-10-01
China
Approved
2008-12-19
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Triptorelin Pamoate?
Approved indications include: 性早熟, Prostate cancer.
When does the Triptorelin Pamoate patent expire?
No public expiry year is available for Triptorelin Pamoate yet; this page updates once verified.
How do I get a quote for Triptorelin Pamoate intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-27